---
title: "Citi Raises WUXI APPTEC  TP to HKD215 as Interim Results Far Exceed Expectations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294902471.md"
description: "Citi raised WUXI APPTEC's target price to HKD215 and maintained a Buy rating, citing interim results that significantly exceeded expectations due to strong demand and late-stage CMO projects. The company raised its 2026 revenue guidance to RMB58.5-60.5 billion. Consequently, Citi lifted 2026-2028 revenue forecasts by 8% and EPS estimates by 15-19%, reflecting higher revenue guidance and margin improvements."
datetime: "2026-08-05T03:01:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294902471.md)
  - [en](https://longbridge.com/en/news/294902471.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294902471.md)
generator: "portal-rs"
---

# Citi Raises WUXI APPTEC  TP to HKD215 as Interim Results Far Exceed Expectations

Citi published a research report stating that strong demand across WUXI APPTEC (02359.HK) +3.800 (+2.098%) Short selling $1.17B; Ratio 33.055% 's business segments and contributions from more late-stage CMO projects drove interim results this year to significantly exceed expectations. Management raised its 2026 revenue guidance to between RMB58.5 billion and RMB60.5 billion, with continuing operations revenue expected to grow 35% to 39% YoY, factoring in a 3 to 5 ppts foreign exchange impact from USD depreciation.

In 1H26, the company's backlog for continuing operations increased by about 30%, while newly signed orders grew by more than 40% YoY. Small molecule CDMO became the engine of accelerating growth, with the small molecule development and manufacturing business rising 73% YoY. Mid- to late-stage pipeline revenue now accounts for more than 50% of total revenue, while over 80% of late-stage and commercialization projects originated from internal early-stage pipelines.

Citi raised its TP on WUXI APPTEC (02359.HK) +3.800 (+2.098%) Short selling $1.17B; Ratio 33.055% from HKD183 to HKD215 and maintained its Buy rating. The broker also lifted its 2026-2028 revenue forecasts by 8% and raised EPS forecasts by 18%, 19% and 15%, respectively, to reflect higher revenue guidance and margin improvement. (gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-04 16:25.)

### Related Stocks

- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [WuXi AppTec files HKEX next-day disclosure return, share capital rises on 7,166,606 H-share conversion](https://longbridge.com/en/news/297883422.md)
- [WuXi AppTec files HKEX next-day disclosure return reporting 6,827,131 new H shares from bond conversion](https://longbridge.com/en/news/298010654.md)
- [20:00 ETWuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion](https://longbridge.com/en/news/297441220.md)
- [WUXI APPTEC  to Early Redeem Convertible Bonds Due 2027 with Principal of RMB4.973 Billion](https://longbridge.com/en/news/297424830.md)
- [WuXi AppTec files HKEX next-day return, lifts share capital by 13,631,632 H shares on bond conversion at HKD 153 each](https://longbridge.com/en/news/297310563.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**